Endothelial Targets in Stroke: Translating Animal Models to Human.
暂无分享,去创建一个
Michael M. Wang | R. Keep | G. Xi | Y. Hua | J. Xiang | S. Stamatovic | A. Andjelkovic
[1] D. Tancredi,et al. Exacerbated brain edema in a rat streptozotocin model of hyperglycemic ischemic stroke: Evidence for involvement of blood–brain barrier Na–K–Cl cotransport and Na/H exchange , 2019, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] S. Doré,et al. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. , 2019, American journal of physiology. Cell physiology.
[3] T. Magnus,et al. The cerebral endothelial cell as a key regulator of inflammatory processes in sterile inflammation , 2019, Journal of Neuroimmunology.
[4] Zhiping Hu,et al. A review of the role of cav-1 in neuropathology and neural recovery after ischemic stroke , 2018, Journal of Neuroinflammation.
[5] R. Keep,et al. Claudin-1-Dependent Destabilization of the Blood–Brain Barrier in Chronic Stroke , 2018, The Journal of Neuroscience.
[6] J. Badaut,et al. Involvement of caveolin-1 in neurovascular unit remodeling after stroke: Effects on neovascularization and astrogliosis , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] W. Fang,et al. Immune Cells After Ischemic Stroke Onset: Roles, Migration, and Target Intervention , 2018, Journal of Molecular Neuroscience.
[8] Yao Yao. Basement membrane and stroke , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] J. Simard,et al. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date , 2018, Drug design, development and therapy.
[10] J. Griffin,et al. Activated protein C, protease activated receptor 1, and neuroprotection. , 2018, Blood.
[11] Michael M. Wang,et al. Expression of periaxin (PRX) specifically in the human cerebrovascular system: PDZ domain-mediated strengthening of endothelial barrier function , 2018, Scientific Reports.
[12] Lee Kissel,et al. Immune responses in stroke: how the immune system contributes to damage and healing after stroke and how this knowledge could be translated to better cures? , 2018, Immunology.
[13] J. Ryu,et al. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics , 2018, Nature Reviews Neuroscience.
[14] Guiling Xiang,et al. Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator , 2018, Clinical Neurology and Neurosurgery.
[15] Zhiqiang Ma,et al. Focusing on claudin-5: A promising candidate in the regulation of BBB to treat ischemic stroke , 2017, Progress in Neurobiology.
[16] M. Bennett,et al. Blood-brain barrier dysfunction and recovery after ischemic stroke , 2017, Progress in Neurobiology.
[17] M. Papa,et al. Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases , 2017, International journal of molecular sciences.
[18] C. Iadecola. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease , 2017, Neuron.
[19] J. Griffin,et al. Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C , 2017, Neuropharmacology.
[20] Mohammad Hossein Khosravi,et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.
[21] R. Medcalf,et al. Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin , 2017, PloS one.
[22] Takenori Yamaguchi,et al. Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[23] Hülya Bayır,et al. The far-reaching scope of neuroinflammation after traumatic brain injury , 2017, Nature Reviews Neurology.
[24] M. Elkind,et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial , 2017, The Lancet Neurology.
[25] D. Lawrence,et al. Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis , 2017, Journal of internal medicine.
[26] Jun Chen,et al. Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke , 2017, Circulation research.
[27] M. Bennett,et al. Endothelium-targeted overexpression of heat shock protein 27 ameliorates blood–brain barrier disruption after ischemic brain injury , 2017, Proceedings of the National Academy of Sciences.
[28] N. Oku,et al. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] C. Sommer. Ischemic stroke: experimental models and reality , 2017, Acta Neuropathologica.
[30] B. Molyneaux,et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial , 2016, The Lancet Neurology.
[31] P. Sandercock,et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis , 2016, The Lancet Neurology.
[32] Xiaoling Chen,et al. The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015 , 2016, Acta pharmaceutica Sinica. B.
[33] R. Coimbra,et al. Injury, inflammation and the emergence of human‐specific genes , 2016, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[34] P. Nahirney,et al. Ultrastructural analysis of blood–brain barrier breakdown in the peri-infarct zone in young adult and aged mice , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[35] C. Lawrence,et al. The blood–brain barrier after stroke: Structural studies and the role of transcytotic vesicles , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[36] R. Keep,et al. Rapid endothelial cytoskeletal reorganization enables early blood–brain barrier disruption and long-term ischaemic reperfusion brain injury , 2016, Nature Communications.
[37] R. Keep,et al. Junctional proteins of the blood-brain barrier: New insights into function and dysfunction , 2016, Tissue barriers.
[38] Zhen Zhao,et al. Establishment and Dysfunction of the Blood-Brain Barrier , 2015, Cell.
[39] A. Buchan,et al. The transient intraluminal filament middle cerebral artery occlusion model as a model of endovascular thrombectomy in stroke , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[40] Sara G. Murray,et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation , 2015, Nature Communications.
[41] F. Shi,et al. Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial , 2015, Circulation.
[42] X. Ji,et al. Normobaric Hyperoxia Slows Blood–Brain Barrier Damage and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in Cerebral Ischemia , 2015, Stroke.
[43] D. Ma,et al. Protective Effects of Non-Anticoagulant Activated Protein C Variant (D36A/L38D/A39V) in a Murine Model of Ischaemic Stroke , 2015, PloS one.
[44] I. Bechmann,et al. Blood—Brain Barrier Breakdown Involves Four Distinct Stages of Vascular Damage in Various Models of Experimental Focal Cerebral Ischemia , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[45] R. Keep,et al. Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury , 2014, Neurobiology of Disease.
[46] P. Bath,et al. Inhibition of Rho‐kinase protects cerebral barrier from ischaemia‐evoked injury through modulations of endothelial cell oxidative stress and tight junctions , 2014, Journal of neurochemistry.
[47] A. Nimmerjahn,et al. Stepwise Recruitment of Transcellular and Paracellular Pathways Underlies Blood-Brain Barrier Breakdown in Stroke , 2014, Neuron.
[48] J. Griffin,et al. Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats , 2013, Stroke.
[49] Á. Corbí,et al. N2 Neutrophils, Novel Players in Brain Inflammation After Stroke: Modulation by the PPAR&ggr; Agonist Rosiglitazone , 2013, Stroke.
[50] K. Furie,et al. Selective ROCK2 inhibition in focal cerebral ischemia , 2013, Annals of clinical and translational neurology.
[51] Yongbo Zhang,et al. Rho kinase: A new target for treatment of cerebral ischemia/reperfusion injury , 2013, Neural regeneration research.
[52] H. Hara,et al. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator , 2012, Neuroscience.
[53] R. Keep,et al. Relocalization of Junctional Adhesion Molecule A during Inflammatory Stimulation of Brain Endothelial Cells , 2012, Molecular and Cellular Biology.
[54] D. Stern,et al. Cilostazol Reduces the Risk of Hemorrhagic Infarction After Administration of Tissue-Type Plasminogen Activator in a Murine Stroke Model , 2012, Stroke.
[55] R. Takahashi,et al. Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia , 2012, Experimental Neurology.
[56] Z. Wang,et al. Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage , 2011, European Journal of Clinical Pharmacology.
[57] K. Arai,et al. Cellular Mechanisms of Neurovascular Damage and Repair After Stroke , 2011, Journal of child neurology.
[58] T. Iwama,et al. Phosphodiesterase-III Inhibitor Prevents Hemorrhagic Transformation Induced by Focal Cerebral Ischemia in Mice Treated with tPA , 2010, PloS one.
[59] G. D. del Zoppo. Acute anti‐inflammatory approaches to ischemic stroke , 2010, Annals of the New York Academy of Sciences.
[60] C. Sommer,et al. Oxygen Therapy Reduces Secondary Hemorrhage after Thrombolysis in Thromboembolic Cerebral Ischemia , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[61] Susan C Fagan,et al. Minocycline and Tissue-Type Plasminogen Activator for Stroke: Assessment of Interaction Potential , 2009, Stroke.
[62] D. Stewart,et al. Expression of endothelial phosphorylated caveolin‐1 is increased in brain injury , 2009, Neuropathology and applied neurobiology.
[63] Ken Arai,et al. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke , 2009, BMC Neuroscience.
[64] K. Liu,et al. Normobaric Hyperoxia Reduces the Neurovascular Complications Associated With Delayed Tissue Plasminogen Activator Treatment in a Rat Model of Focal Cerebral Ischemia , 2009, Stroke.
[65] S. D. de Morais,et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. , 2009, Pharmacological research.
[66] Marc Fisher,et al. Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations , 2009, Stroke.
[67] Toru Yamashita,et al. Dissociation and Protection of the Neurovascular Unit after Thrombolysis and Reperfusion in Ischemic Rat Brain , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[68] S. Nagahiro,et al. Edaravone, a Free Radical Scavenger, Inhibits MMP-9–Related Brain Hemorrhage in Rats Treated With Tissue Plasminogen Activator , 2009, Stroke.
[69] K. Rhodes,et al. Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke , 2008, Stroke.
[70] Myron D. Ginsberg,et al. Neuroprotection for ischemic stroke: Past, present and future , 2008, Neuropharmacology.
[71] Ulf Eriksson,et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke , 2008, Nature Medicine.
[72] J. Simard,et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications , 2007, The Lancet Neurology.
[73] R. Keep,et al. Protein Kinase Cα-RhoA Cross-talk in CCL2-induced Alterations in Brain Endothelial Permeability* , 2006, Journal of Biological Chemistry.
[74] Takeshi Hayashi,et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain , 2004, Neurological research.
[75] John H. Zhang,et al. Molecular Determinants of the Prothrombogenic and Inflammatory Phenotype Assumed by the Postischemic Cerebral Microcirculation , 2003, Stroke.
[76] R. Keep,et al. Blood—Brain Barrier Permeability and Brain Concentration of Sodium, Potassium, and Chloride during Focal Ischemia , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[77] K. Takakura,et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. , 1992, Journal of neurosurgery.
[78] H. C. Moises,et al. Blood to Brain Sodium Transport and Interstitial Fluid Potassium Concentration during Early Focal Ischemia in the Rat , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[79] U. Degirolami,et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. , 1985, Science.
[80] J. Garcìa,et al. Temporary regional cerebral ischemia in the cat. A model of hemorrhagic and subcortical infarction. , 1977, Journal of neuropathology and experimental neurology.
[81] A. Ommaya,et al. Temporary Occlusion of the Middle Cerebral Artery in the Monkey: Clinical and Pathological Observations , 1970, Stroke.
[82] R. Shenkar,et al. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations , 2017, Stroke.
[83] M. O’Donnell. Blood-brain barrier Na transporters in ischemic stroke. , 2014, Advances in pharmacology.